90 Miles From Tyranny

Monday, October 4, 2021

Professor suspended for refusing to give Black students easier final exams sues UCLA

A UCLA professor who was briefly suspended after declining a request that Black students get easier final exams after George Floyd’s death sued the school Wednesday, accusing it of defamation and loss of financial opportunities.

Gordon Klein, a lecturer at UCLA’s Anderson School of Management who has taught there for decades, filed the lawsuit in state court against the school’s dean, Antonio Bernardo, the University of California Board of Regents, and a host of unnamed “co-conspirators.”

“I did this because the school has continued to retaliate against me, and other scholars are facing retaliation, and I thought it was important for someone to step up and say, ‘enough,’” Mr. Klein told The Washington Times. “I have the legal skills and training to do so, so I’m stepping up.”

Mr. Bernardo and the others effectively organized a smear campaign against Mr. Klein after he turned down a “non-Black” student’s request that Black students in his class be given “no harm” final exams because of emotional turmoil Floyd’s death may have caused, the lawsuit alleges.

Through a spokeswoman, Mr. Bernardo declined to comment on the suit.

UCLA said it “has general procedures and principles that uphold freedom of expression and freedom of intellectual inquiry while also facilitating a learning, working, and living environment that is free from discrimination, harassment or retaliation.”

Following Floyd’s killing by a Minneapolis policeman in May 2020, an organized campaign began at UCLA known as “Letter Writing for Finals Accomodations for Black Students,” in which professors were urged to offer what amounted to preferential treatment to...

Before You Click On The "Read More" Link,

Please Only Do So If You Are Over 21 Years Old.

If You are Easily Upset, Triggered Or Offended, This Is Not The Place For You.

Please Leave Silently Into The Night......

You have come across a mystery box. But what is inside?

It could be literally anything from the serene to the horrific,

from the beautiful to the repugnant,

from the mysterious to the familiar.

If you decide to open it, you could be disappointed,

you could be inspired, you could be appalled.

This is not for the faint of heart or the easily offended.

You have been warned.

Hey Joe, Where You Going With All That Blood On Your Hands?

Girls With Guns

No scoundrel is so stupid as to not find a reason for his vile conduct.

Marked Unsafe From Milley's Drones.

News Of The World!

The Jab Creates Blood Clots.

When blood clots form within blood vessels they can obstruct blood flow, a condition called thrombosis. That could mean trouble. If a clot in an artery breaks free and travels through the circulatory system, it can cause blockages affecting the heart, lungs, and other organs—potentially shutting them down.

Creating A...

Sheer Heart Attack.

Hey, hey, hey, hey

It was the DNA
Hey, hey, hey, hey
That made me this way
Do you know, do you know, do you know
Just how I feel?
Do you know, do you know, do you know
Just how I feel?

Sheer heart attack
Sheer heart attack
Real cardiac
I feel so
Inar-inar-inar-inar-inar-inar-inar-inarticulate

Merck's New Pill Molnupiravir May Be A Trojan Horse To Change Your DNA.....

Molnupiravir was developed for the treatment of Influenza. According to whistleblower complaint Molnupiravir has mutagenic properties and may change your DNA. Now, Molnupiravir has been repurposed for COVID-19. Merck has entered into agreements with Indian manufacturers and has also announced $5 million of donations to enter into Indian market. Here is all you need to know about Merck’s Covid pill Molnupiravir.

Molnupiravir was developed for Influenza

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza.

It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.

The drug was developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE).

It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.

Molnupiravir may change your DNA

In April 2020, Rick Bright, who was removed as head of the Biomedical Advanced Research and Development Authority (BARDA) before the approval of the drug, submitted a whistleblower complaint asserting that Ridgeback pressured BARDA to provide funding to manufacture EIDD-2801 despite Bright’s concerns that similar drugs in its class have mutagenic properties.

A previous company, Pharmasset, that had investigated the Molnupiravir’s active ingredient had abandoned it over similar concerns.

In genetics, a mutagen is a physical or chemical agent that permanently changes genetic material, usually DNA, in an organism and thus increases the frequency of mutations above the natural background level.

As many mutations can cause cancer, such mutagens are therefore carcinogens, although not all necessarily are. All mutagens have characteristic mutational signatures with some chemicals becoming mutagenic through cellular processes.

These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on Molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020.

At that time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.

Merck’s Covid Pill Molnupiravir

In late July 2020 Merck, which had been partnering with Ridgeback Biotherapeutics on developing the drug, announced its intention to move Molnupiravir to late stage trials beginning in September 2020.

On October 19, 2020, Merck began a one year Stage 2/3 trial that focused on...